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Available online 20 July 2016Objective: Orolingual angioedema (OA) is a well known early complication of treatment with alteplase in ische-
mic stroke patients. Our aim was to study risk factors for OA in these patients, namely insular cortex ischemia.
Methods: Retrospective case-cohort study using the prospective registry of all consecutive ischemic stroke pa-
tients submitted to intravenous thrombolysis with alteplase. Clinical data was retrieved from the registry and
medical records. Two independent observers evaluated early signs of insular cortex ischemia on pre-thrombol-
ysis computed tomography (CT) and of insular cortex infarct on early follow-up imaging. Univariate and multi-
variate analysis were performed to identify predictors of OA.
Results: Of the 659 patients with acute ischemic stroke treated with alteplase, 32 developed OA (4.9%, 95%CI =
3.3–6.6). Frequency of early signs of insular cortex ischemia on pre-thrombolysis CT and of insular cortex infarct
on follow-up imaging was similar in patients with and without OA (p=0.241 and p=0.145, respectively). The
only independent predictors of OA occurrence were female sex (OR= 5.47, 95%CI = 1.98–15.10) and angioten-
sin-converting enzyme inhibitor (ACE-I) use (OR = 3.87, 95%CI = 1.71–8.75).
Conclusions: Female sex and ACE-I use are independent risk factors for OA occurrence in ischemic stroke patients
treated with alteplase. Early signs of insular cortex ischemia on pre-thrombolysis CT were not significantly asso-
ciated with OA.





Orolingual angioedema (OA) is a well known early complication of
alteplase when used for treatment of acute ischemic stroke, occurring
in up to 7.9% of patients [1–3]. It consists of painless swelling of lips,
tongue, face and occasionally oropharynx, occurring shortly after intra-
venous alteplase administration, which usually resolves during the first
24 h.Most case-control studies recognize use of angiotensin-converting
enzyme inhibitors (ACE-I) as the main risk factor for occurrence of this
potentially serious adverse event [1–4], and other authors found a
higher frequency of insular ischemia in patients who developed angio-
edema [2,5]. In addition to contribute to several high order complex ce-




.com (M. Ribeiro),responses and it is involved in cardiac and vascular autonomic tone reg-
ulation and visceromotor control. The imbalance of sympathetic and
parasympathetic control induced by insular ischemic lesions was pro-
posed by several authors to contribute to the pathophysiology of OA
[2–5]. Our aim was to study risk factors for OA occurrence in ischemic
stroke patients treated with alteplase, in particular association with in-
sular ischemia.
2. Materials and methods
We performed a retrospective case-cohort study using the prospec-
tive registry of consecutive ischemic stroke patients submitted to intra-
venous thrombolysis with alteplase, in the first author's hospital,
between February 2007 and January 2016. Demographic and clinical
data, namely occurrence and characteristics of OA, was collected from
the registry and confirmed by analysis of individual medical records.
OA is routinely searched by the treating physician, as determined by
our StrokeUnit protocol, every 15min during thefirst hour after throm-
bolysis and every 30 min after the first hour up to 6 h. Insular cortex is-
chemia in baseline pre-thrombolysis computed tomography (CT) was
Table 1











Female sex 343 (54.7) 27 (84.4) 0.001⁎
Age (years) 74 (65–79) 78 (71–81) 0.054
Arterial hypertension 409 (65.2) 28 (87.5) 0.011⁎
Diabetes 128 (20.4) 7 (21.9) 0.842
Dyslipidemia 274 (43.7) 71 (53.1) 0.295
Ischemic heart disease 45 (7.2) 3 (9.4) 0.641⁎
Autoimmune co-morbidity 5 (0.8) 0 0.612⁎
Current ACE-I use 139 (22.2) 16 (50.0) b0.001
Current ARB use 176 (28.2) 9 (28.1) 0.992
Current steroid or imunossupressor use 14 (2.2) 2 (6.3) 0.180⁎
Vertebrobasilar circulation stroke 57 (9.1%) 3 (9.4) 1.000⁎
Admission NIHSS 14 (10–19) 17 (10−21) 0.157
Systolic BP (mmHg) 145 (130–162) 155
(132–168)
0.334
Diastolic BP (mmHg) 81 (72–91) 79 (72–93) 0.996
Admission BP N185/105 mmHg 77 (12.5) 4 (12.5) 1.000⁎
Urgent captopril use before/during
thrombolysis
35 (5.6) 2 (6.3) 0.700⁎
Urgent labetalol use before/during
thrombolysis
57 (9.1) 7 (21.9) 0.018
Admission glucose 125 (108–158) 135.5
(113–161)
0.196
Vomiting before/during thrombolysis 72 (11.5) 9 (28.1) 0.005
Urgent metoclopramide use
before/during thrombolysis
39 (6.2) 8 (25.0) b0.001
ASPECTS/pcASPECTS 9 (8–10) 8.5 (7–10) 0.494





67 (10.7) 3 (9.4) 1.000⁎
Hyperacute endovascular
revascularization
49 (7.8) 1 (3.1) 0.502⁎
Early signs of insular cortex ischemia
on pre-thrombolysis CT†
202 (33.7) 14 (43.8) 0.241
Insular cortex infarct on follow-up
neuroimaging
309 (49.3) 20 (62.5) 0.145
MRI as follow-up imaging 80 (12.7) 3 (9.4) 0.786⁎
Results are represented as n (%) ormedian (interquartile range). Pearson's chi square used
for categorical variables except where noted (⁎ Fisher's exact test). Mann-Whitney U test
used for continuous variables. ACE-I: angiotensin-converting enzyme inhibitor. ARB: an-
giotensin II receptor blocker. NIHSS: National Institute of Health Stroke Scale. BP: blood
pressure. ASPECTS: Alberta Stroke Program Early Computed Tomography Score.
pcASPECTS: posterior circulation ASPECTS. CT: computed tomography.MRI:magnetic res-
onance imaging.
† Data available for 632 patients (27 patients with no available pre-thrombolysis CT for
analysis).
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partial or total insular cortex hypoattenuation or focal swelling [6]. Insu-
lar cortex infarct on follow-up imaging during the first 7 days was also
independently evaluated by authors JMA and MR, and was defined as
new hypodense lesion involving part or the whole insular cortex in CT
or insular cortex restricted diffusion lesion on magnetic resonance im-
aging (MRI) when available. Both observers were blinded for the occur-
rence of angioedema, interobserver agreement was determined using
Cohen's kappa coefficient, and interobserver disagreements were sub-
sequently settled by consensus. Groups of patientswith andwithout an-
gioedema were compared using χ2 and Mann-Whitney U tests as
appropriate. Binary logistic regressionwas calculated using angioedema
as the dependent variable and variables with p b 0.05 in univariate anal-
ysis as the independent variables. Early signs of insular cortex ischemia
on pre-thrombolysis CT scan was also entered in the model as an inde-
pendent variable. Statistical threshold for significance was p b 0.05. The
study complies with the Helsinki Declaration and the Hospital de Braga
ethics committee requirements for clinical research.
3. Results
Of the 659 patients with acute ischemic stroke submitted to intrave-
nous thrombolysis with alteplase, 32 developed OA (4.9%, 95% confi-
dence interval [95%CI] = 3.3–6.6), at a median time of 60 min after
the alteplase bolus (range = 15–720). OA was strictly unilateral in 15
patients (contralateral to ischemia in 10, ipsilateral to ischemia in 5)
and bilateral in 17 patients. Accompanying manifestations included
bronchospasm and peripheral desaturation (n= 9), truncal or facial ur-
ticaria (n = 2) and hemodynamic instability (n = 2). The majority of
patients were treated with steroids or antihistaminic drugs (n = 29)
and subcutaneous adrenalin was used in 10 patients. No patient re-
quired emergent airway management and in 3 patients OA resolved
spontaneously. In univariate analysis (Table 1), patients who developed
OA were more frequently women, more frequently had arterial hyper-
tension and were medicated with ACE-I. Despite no differences in pre-
treatment blood pressure values in the two groups, urgent labetalol
was usedmore frequently in the OA group. Vomiting and use of intrave-
nous metoclopramide before or during thrombolysis were also more
frequent in the OA group. Frequency of early signs of insular cortex is-
chemia on pre-thrombolysis CT and frequency of insular cortex infarct
on follow-up neuroimaging were similar in patients with and without
OA (p = 0.241 and p = 0.145, respectively).
Interobserver agreement was good for both pre-thrombolysis insu-
lar ischemia on CT (kappa = 0.69, p b 0.001) and insular infarct in fol-
low-up imaging (kappa = 0.78, p b 0.001). In the logistic regression
model (Table 2), the only independent predictors for OA were female
sex (odds ratio [OR] = 5.47, 95%CI = 1.98–15.10) and current ACE-I
use (OR = 3.87, 95%CI = 1.71–8.75).
Forced entry of insular cortex infarct on follow-upneuroimaging and
exclusion of early signs of insular ischemia as variables in the regression
model did not change the results (Supplementary Table 1).
4. Discussion
This study is one of the largest studies analyzing clinical predictors of
the occurrence of OA and the largest study which performed a system-
atic, independent and blinded evaluation of occurrence of insular ische-
mic lesions on neuroimaging. Prevalence of OA in patients with acute
ischemic stroke treated with alteplase was 4.9%, which is in accordance
to previous studies [1–4,7]. We found no significant differences in the
frequency of insular cortex ischemic lesions on pre-thrombolysis CT,
and early signs of insular cortex ischemiawere not independent predic-
tors of OA occurrence in multivariate analysis. The clinical significance
of this finding is that early signs of insular cortex ischemia on pre-
thrombolysis CT should not be regarded as a marker of risk for OA. De-
spite thewell known limitation of CT for diagnosis of very early cerebralischemic changes, early signs of insular ischemia on CT had the higher
interobserver agreement among all cerebral regions evaluated in the Al-
berta Stroke Program Early CT Score in a relevant study by Gupta et al.
[8], which supports the clinical value of our findings. A recent study
compared the frequency of insular infarcts in MRI in 19 patients who
developed OA after thrombolysis and 77 selected patients who did not
develop OA and there was no difference [4]. Despite this, these authors
reported a similar frequency of small insular infarcts but a significantly
higher frequency of total insular infarcts in patients with OA, which
should be interpreted with caution because of the scarce number of pa-
tients with total insular infarcts. Higher frequency of insular involve-
ment in OA patients was found by Hill et al. [2], however, a non-
blinded assessment of imaging was performed by the treating physi-
cian, which could have introduced a potential imaging assessment
bias. The high frequency of insular cortex ischemia in OA patients
(80%) found by Werner et al., was evaluated by MRI in 15 patients
with OA, however, patients without OAwere not analyzed [5]. Although
Table 2
Multivariate analysis for orolingual angioedemapredictors using binary logistic regression
model.
Independent variables Odds ratio
(95% confidence interval)
P value
Female sex 5.47 (1.98–15.10) 0.001
Arterial hypertension 1.90 (0.60–6.02) 0.275
Current ACE-I use 3.87 (1.71–8.75) 0.001













ACE-I: angiotensin-converting enzyme inhibitor.
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ischemia for development of alteplase-related OA, our study does not
support the suggestion that insular ischemia plays a key role in its
pathophysiology.
Other case control-studies found a higher frequency of OA inwomen
[3,5] and, in our study, female sexwas an independent risk factor for OA,
which is in accordance to a large cohort study of medication-related an-
gioedema incidence [9]. The reason for this sex difference is not clear,
but may include the influence of sex hormones on the regulation of in-
flammation and an increased Th2 immune response in women [10],
which is further supported by the female predominance of chronic urti-
caria, a condition with a pathophysiology closely linked to acquired an-
gioedema [11].
Current use of ACE-I was independently associatedwith a 4-fold risk
increase in the development of OA. This association iswell known in the
literature and is explained by inhibition of bradykininmetabolization by
ACE-I and concomitant alteplase-mediated bradykinin generation [12]
(Supplementary Fig. 1). The possibility of increased risk of OA in pa-
tients treated with angiotensin receptor blockers [13] was not con-
firmed in our study.
The fact that this is a single center study weakens the statistical
power needed to demonstrate the association of insular ischemia and
OA development, and these results need confirmation in other larger
case-control multicentre studies. Another important limitation of our
study is absence of pre-thrombolysis MRI or perfusion imaging tech-
niques, which could provide more accurate information on insular is-
chemia or insular hypoperfusion, and absence of follow-up MRI in the
majority of patients, which is more sensitive than CT for the diagnosis
of recent small insular infarcts.5. Conclusions
Orolingual angioedemaoccurred in 4.9% of acute ischemic stroke pa-
tients treated with alteplase and the only independent risk factors
foundwere female sex and ACE-I use. Early signs of insular cortex ische-
mia in pre-thrombolysis CT were not significantly associated with
orolingual angioedema occurrence.
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